Clin Asst Prof Koo Si-Lin

About

Dr Koo Si-Lin is a Senior Consultant in Medical Oncology from the National Cancer Centre, Singapore. She graduated from the National University of Singapore with a Bachelor of Medicine, Bachelor of Surgery. She completed her Medical Oncology specialist training in 2014. She has a budding interest in cancer research and is developing her research in cancer immunology. She is actively engaged with researchers in Singhealth and A*STAR in developing translational research.

Education and Training

• MRCP, Royal College of Physicians 
• MMed, National University of Singapore 
• MBBS, National University of Singapore 
  

Professional Appointments and Committee Memberships

• Member, Singapore Society of Oncology
  

Awards

• SingHealth Best Registrar Award 2013
  

Research Interests

• Cancer immunology
• Colorectal cancer
  

Research Trials

• Immune repertoire sequencing, ex-vivo expansion and functional characterisation of cytotoxic tumor infiltrating T lymphocytes in colorectal cancer: a step towards adoptive immunomodulated T cell therapy 
• A Phase III Study of Pembrolizumab (MK-3475) vs Chemotherapy in Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Carcinoma 
  

Publications

• Ng SB, Chua C, Ng M, Gan A, Poon PS, Teo M, Fu C, Leow WQ, Lim KH, Chung A, Koo SL, Choo SP, Ho D, Rozen S, Tan P, Wong M, Burkholder WF, Tan IB. Individualised multiplexed circulating tumour DNA assays for monitoring of tumour presence in patients after colorectal cancer surgery. Sci Rep. 2017 Jan 19;7:40737.
• Simoni Y, Fehlings M, Kløverpris HN, McGovern N, Koo SL, Loh CY, Lim S, Kurioka A, Fergusson JR, Tang CL, Kam MH, Dennis K, Lim TK, Fui AC, Hoong CW, Chan JK, Curotto de Lafaille M, Narayanan S, Baig S, Shabeer M, Toh SE, Tan HK, Anicete R, Tan EH, Takano A, Klenerman P, Leslie A, Tan DS, Tan IB, Ginhoux F, Newell EW. Human Innate Lymphoid Cell Subsets Possess Tissue-Type Based Heterogeneity in Phenotype and Frequency. Immunity. 2017 Jan 17;46(1):148-161. 
• Matsumoto H, Thike AA, Li H, Yeong J, Koo SL, Dent RA, Tan PH, Iqbal J. Increased CD4 and CD8-positive T cell infiltrate signifies good prognosis in a subset of triple-negative breast cancer. Breast Cancer Res Treat. 2016 Apr;156(2):237-47. 
• Ng T, Teo SM, Yeo HL, Shwe M, Gan YX, Cheung YT, Foo KM, Cham MT, Lee JA, Tan YP, Fan G, Yong WS, Preetha M, Loh WK, Koo SL, Jain A, Lee GE, Wong M, Dent R, Yap YS, Ng R, Khor CC, Ho HK, Chan A. Brain-derived neurotrophic factor genetic polymorphism (rs6265) is protective against chemotherapy-associated cognitive impairment in patients with early-stage breast cancer. Neuro Oncol. 2016 Feb;18(2):244-51.
• Matsumoto H, Koo SL, Dent R, Tan PH, Iqbal J. Role of inflammatory infiltrates in triple negative breast cancer. J Clin Pathol. 2015 Jul;68(7):506-10. 
• Adusumalli S, Lee H, Hoi Q, Koo SL, Tan IB, Ng PC. Assessment of Web-Based Consumer Reviews as a Resource for Drug Performance. J Med Internet Res. 2015 Aug 28;17(8):e211. 
• Koo SL, Wen JH, Hillmer A, Cheah PY, Tan P, Tan IB. Current and emerging surveillance strategies to expand the window of opportunity for curative treatment after surgery in colorectal cancer. Expert Rev Anticancer Ther. 2013 Apr;13(4):439-50.